{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:14Z","timestamp":1787026394341,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing\u2019s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effect model was used to estimate pooled effects. Quality assessment was performed with a modified Joanna Briggs\u2019s Institute tool and the risk of publication bias was addressed through Egger\u2019s regression and the three-parameter selection model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The electronic search identified 179 and 122 articles respectively for acromegaly and CD. After study selection, six studies considering patients with acromegaly and three with CD fulfilled the eligibility criteria. Overall, 37.7% (95%CI: [18.7%; 61.5%]) of acromegalic patients and 41.2% (95%CI: [22.9%; 62.3%]) of CD patients achieved significant tumor shrinkage. We identified high heterogeneity, especially in acromegaly (I\n                      <jats:sup>2<\/jats:sup>\n                      of 90% for acromegaly and 47% for CD), according to the low number of studies included.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>PAS treatment is effective in reducing tumor size, especially in acromegalic patients. This result strengthens the role of PAS treatment in pituitary adenomas, particularly in those with an invasive behavior, with progressive growth and\/or extrasellar extension, with a low likelihood of surgical gross-total removal, or with large postoperative residual tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022328152<\/jats:uri>\n                      , identifier CRD42022328152\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.935759","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T01:25:09Z","timestamp":1656638709000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Alessandro","family":"Mondin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tizianel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.08.007","article-title":"Expression of Somatostatin Receptors, SSTR2A and SSTR5, in 108 Endocrine Pituitary Tumors Using Immunohistochemical Detection With New Specific Monoclonal Antibodies","volume":"45","author":"Chinezu","year":"2014","journal-title":"Hum Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S37314","article-title":"Clinical Use of Pasireotide for Cushing's Disease in Adults","volume":"11","author":"Ceccato","year":"2015","journal-title":"Ther Clin Risk Manage"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for Acromegaly Management: An Update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide Versus Continued Treatment With Octreotide or Lanreotide in Patients With Inadequately Controlled Acromegaly (PAOLA): A Randomised, Phase 3 Trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for Acromegaly: Long-Term Outcomes From an Extension to the Phase III PAOLA Study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 Months: Results From the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study","volume":"18","author":"Sheppard","year":"2015","journal-title":"[Published Correction Appears in Pituitary]"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching Patients With Acromegaly From Octreotide to Pasireotide Improves Biochemical Control: Crossover Extension to a Randomized, Double-Blind, Phase III Study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs","volume":"10","author":"Gadelha","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12431","article-title":"Pasireotide Treatment Significantly Improves Clinical Signs and Symptoms in Patients With Cushing's Disease: Results From a Phase III Study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and Safety of Once-Monthly Pasireotide in Cushing's Disease: A 12 Month Clinical Trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-Term Treatment of Cushing's Disease With Pasireotide: 5-Year Results From an Open-Label Extension Study of a Phase III Trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14081","article-title":"Long-Term Efficacy and Safety of Once-Monthly Pasireotide in Cushing's Disease: A Phase III Extension Study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.732240","article-title":"Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Sim\u00f5es Corr\u00eaa Galendi","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 Mutational Status may Predict Drug Susceptibility in Corticotroph Adenomas of Cushing's Disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing Pasireotide-Associated Hyperglycemia: A Randomized, Open-Label, Phase IV Study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2347","article-title":"Primary Treatment of Acromegaly With Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of its Efficacy in the Control of Disease Activity and Tumor Shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor Shrinkage With Lanreotide Autogel 120 Mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0356","article-title":"T2-Weighted MRI Signal Predicts Hormone and Tumor Responses to Somatostatin Analogs in Acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO Framework to Improve Searching PubMed for Clinical Questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement [Published Correction Appears in JAMA","volume":"319","author":"McInnes","year":"2018","journal-title":"2019 Nov 26;322(20):2026]. JAMA."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological Quality of Case Series Studies: An Introduction to the JBI Critical Appraisal Tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in Acromegaly Patients Treated With a Combination Therapy: A Real-Life Study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01185-w","article-title":"Real-World Experience With Pasireotide-LAR in Resistant Acromegaly: A Single Center 1-Year Observation","volume":"25","author":"Stelmachowska-Bana\u015b","year":"2022","journal-title":"Pituitary."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1818-7","article-title":"The Medical Treatment With Pasireotide in Cushing's Disease: An Italian Multicentre Experience Based on \"Real-World Evidence\"","volume":"64","author":"Pivonello","year":"2019","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.014\u201d","article-title":"Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis","volume":"21","author":"Leonart","year":"2018","journal-title":"Value Health"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0528","article-title":"Comparative Efficacy Of Medical Treatment For Acromegaly: A Systematic Review And Network Meta-Analysis Of Integrated Randomized Trials And Observational Studies","volume":"26","author":"Qiao","year":"2020","journal-title":"Endocr Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of Cabergoline in Acromegaly: A Meta-Analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.05.006","article-title":"The Role of Dopamine Agonists in Pituitary Adenomas","volume":"49","author":"Giraldi","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas During Treatment With Pegvisomant: A Prospective Multicenter Study","volume":"95","author":"uhk","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1742","article-title":"Somatotroph Tumor Progression During Pegvisomant Therapy: A Clinical and Molecular Study","volume":"96","author":"Marazuela","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential Antitumour Activity of Pasireotide on Pituitary Tumours in Acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing's Disease: A Large Retrospective Multicenter Study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533","article-title":"The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment With the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on Diagnosis and Management of Cushing's Disease: A Guideline Update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and Pasireotide Treatment for Aggressive Pituitary Adenoma: Expertise at a Tertiary Care Center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J Neurooncol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and Safety of Osilodrostat in Patients With Cushing's Disease (LINC 3): A Multicentre Phase III Study With a Double-Blind, Randomised Withdrawal Phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in Adrenal Steroidogenesis Inhibitors for Cushing's Syndrome - A Practical Guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0853-3","article-title":"A Prospective Longitudinal Study of Pasireotide in Nelson's Syndrome","volume":"21","author":"Daniel","year":"2018","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1497","article-title":"Sustained Improvements in Plasma ACTH and Clinical Status in a Patient With Nelson's Syndrome Treated With Pasireotide LAR, a Multireceptor Somatostatin Analog","volume":"98","author":"Katznelson","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40842-020-00110-7","article-title":"Rapid Response of Nelson's Syndrome to Pasireotide in Radiotherapy-Naive Patient","volume":"6","author":"He","year":"2020","journal-title":"Clin Diabetes Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.935759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T01:25:12Z","timestamp":1656638712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.935759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":45,"alternative-id":["10.3389\/fendo.2022.935759"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.935759","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"article-number":"935759"}}